94
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Budget impact analysis of the freestyle libre flash continuous glucose monitoring system® in patients with diabetes mellitus type 1 in Chile

ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 353-363 | Received 18 Aug 2022, Accepted 19 Jan 2023, Published online: 31 Jan 2023

References

  • Tan SY, Mei Wong JL, Sim YJ, et al. Type 1 and 2 diabetes mellitus: a review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr. 2019;13(1):364–372.
  • Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes Atlas, 9th edition [Internet]. Diabetes Res Clin Pract. 2019;157:107843. .
  • Williams R, Karuranga S, Malanda B, et al. Global and regional estimates and projections of diabetes-related health expenditure: results from the international diabetes federation diabetes atlas. 9th Diabetes Res Clin Pract. 2020;162:108072.
  • Tao B, Pietropaolo M, Atkinson M, et al. Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method. PLoS One. 2010;5(7):e11501.
  • Margozzini P, Passi Á. Encuesta Nacional de Salud, ENS 2016–2017: un aporte a la planificación sanitaria y políticas públicas en Chile [Internet]. ARS MEDICA Revista de Ciencias Médicas. 2018;43(1):30–34.
  • Carrasco E, Pérez-Bravo F, Dorman J, et al. Increasing incidence of type 1 diabetes in population from Santiago of Chile: trends in a period of 18 years (1986–2003) [Internet]. Diabetes Metab Res Rev. 2006;22(1):34–37. .
  • Pathak V, Pathak NM, O’Neill CL, et al. Therapies for Type 1 Diabetes: current Scenario and future perspectives. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419844521.
  • Ministerio de Salud de Chile. Guía Clínica AUGE Diabetes Mellitus tipo 1 [Internet]. Serie Guías Clínicas, MINSAL. 2013 [cited 2021 Jun]. Available from: http://www.repositoriodigital.minsal.cl/bitstream/handle/2015/522/Diabetes-Mellitus-tipo-1-2013.pdf?sequence=1&isAllowed=y.
  • Blum A. Freestyle Libre Glucose Monitoring System [Internet]. Clin Diabetes. 2018;36(2):203–204. .
  • Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254–2263.
  • Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, et al. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia. 2018;61(3):539–550.
  • Fundación Diabetes Juvenil de Chile. Freestyle Libre [Internet]. [cited 2020 Jul 31]. Available from: http://www.diabeteschile.cl/producto/freestyle-libre-sensor.
  • Bitrán R, Escobar L, Gassibe P. After Chile’s health reform: increase in coverage and access, decline in hospitalization and death rates [Internet]. Health Affairs. 2010;29(12):2161–2170. Available from.
  • Shi L, Hellmund R. Cost comparison of flash continuous glucose monitoring with self-monitoring of blood glucose in adults with type 1 or type 2 diabetes using intensive insulin—from a US private payer perspective. US Endocrinol. 2020;16(1):24
  • Hellmund R, Weitgasser R, Blissett D. Cost calculation for a flash glucose monitoring system for UK adults with type 1 diabetes mellitus receiving intensive insulin treatment. Diabetes Res Clin Pract. 2018;138:193–200.
  • Oyagüez I, Merino-Torres JF, Brito M, et al. Cost analysis of the flash monitoring system (FreeStyle Libre 2) in adults with type 1 diabetes mellitus. BMJ Open Diabetes Res Care. Internet]. 2020;8. Available from.;(1):e001330. http://dx.doi.org/10.1136/bmjdrc-2020-001330
  • Bilir SP, Hellmund R, Wehler B, et al. Cost-effectiveness analysis of a flash glucose monitoring system for patients with type 1 diabetes receiving intensive insulin treatment in Sweden. Eur Endocrinol. 2018;14(2):73–79.
  • Healthcare Improvement Scotland, What is the clinical and cost effectiveness of Freestyle Libre® flash glucose monitoring for patients with diabetes mellitus treated with intensive insulin therapy? [Internet]. [cited 2022 May 3]. Available from: https://shtg.scot/media/1799/freestyle-libre-flash-glucose-monitoring-shtg-evidence-note-81-endocrinology-and-diab.pdf.
  • Zhao X, Ming J, Qu S, et al. Cost-effectiveness of flash glucose monitoring for the management of patients with type 1 and patients with Type 2 diabetes in China. Diabetes Ther. 2021;12(12):3079–3092.
  • Gil-Ibáñez MT, Aispuru GR. Cost-effectiveness analysis of glycaemic control of a glucose monitoring system (FreeStyle Libre®) for patients with type 1 diabetes in primary health care of Burgos. Enferm Clin. 2020;30(2):82–88.
  • Bilir SP, Li H, Wehler EA, et al. Cost effectiveness analysis of a flash glucose monitoring system for type 1 diabetes (T1DM) patients receiving intensive insulin treatment in Europe and Australia [Internet]. Value Health. 2016;19(7):A697–A698. Available from.
  • Blissett R, Blissett D, Levrat-Guillen F, et al. FreeStyle libre flash glucose monitoring system for people with type 1 diabetes in the UK: a budget impact analysis [Internet]. BMJ Open Diabetes Res Care. 2022;10(2):e002580. Available from.
  • World Bank, Official exchange rate (LCU per US$, period average) - Chile [Internet] . [ cited 2021 Jul 16]. cited: https://data.worldbank.org/indicator/PA.NUS.FCRF?locations=CL.
  • Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5–14.
  • Ministerio de Salud de Chile, Estudio de Verificación del Costo Esperado Individual Promedio por Beneficiario del Conjunto Priorizado de Problemas de Salud con Garantías Explicitas. 2018; Available from: http://www.biblioteca.digital.gob.cl/handle/123456789/2328.
  • NICE UK, Overview | FreeStyle Libre for glucose monitoring | Advice . [cited 2020 Jul 31]; Available from: https://www.nice.org.uk/advice/mib110.
  • Diabetes UK. NHS to provide flash glucose monitoring for people with Type 1 diabetes [Internet]. 2018. Available from: https://www.diabetes.org.uk/about_us/news/flash-on-nhs.
  • Instituto de Estadísticas de Chile, . [cited 2020 Jul 31]. Available from: https://www.ine.cl/estadisticas/.
  • Munoz CE, Weinstock RS, Brown TD, et al. Women and the American Diabetes Association. Diabetes. 2021;70(8):1638–1639.
  • Khunti K, Alsifri S, Aronson R, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18(9):907–915.
  • Tomky D. Detection, prevention, and treatment of hypoglycemia in the hospital [Internet]. Diabetes Spectr. 2005;18(1):39–44. =.
  • Veronese G, Marchesini G, Forlani G, et al. Costs associated with emergency care and hospitalization for severe hypoglycemia [Internet]. Nutr Metab Cardiovasc Dis. 2016;26(4):345–351.
  • Heller SR, Frier BM, Hersløv ML, et al. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources. Diabet Med. 2016;33(4):471–477.
  • Ministerio de Salud de Chile. Garantías Explícitas en Salud (GES) [Internet]. MINSAL. 2019 [cited 2021 Jun]. Available from: http://www.supersalud.gob.cl/difusion/665/w3-propertyvalue-1962.html.
  • Pichon-Riviere A, Drummond M, Martí SG, et al. Aplicación de la evidencia económica en la evaluación de tecnologías sanitarias y la toma de decisiones sobre asignación de recursos sanitarios en América Latina [Internet]. 2021 [cited 2021 Jun]. Available from: https://www.argentina.gob.ar/sites/default/files/nt-consideraciones-hta-la-2021.pdf.
  • Nuijten MJC, Mittendorf T, Persson U. Practical issues in handling data input and uncertainty in a budget impact analysis [Internet]. Eur J Health Econ. 2011;12(3):231–241. Available from.
  • McCabe C, Paulden M, Awotwe I, et al. One-way sensitivity analysis for probabilistic cost-effectiveness analysis: conditional expected incremental net benefit [Internet]. PharmacoEconomics. 2020;38(2):135–141.
  • American Diabetes Association. Standards of medical care in diabetes 2017. Diabetes Care [Internet]. 2017;40. Available from: https://care.diabetesjournals.org/content/diacare/suppl/2016/12/15/40.Supplement_1.DC1/DC_40_S1_final.pdf.
  • National Clinical Guideline Centre (UK). Type 1 diabetes in adults: diagnosis and management. London: National Institute for Health and Care Excellence (UK); 2015.
  • Parekh W, Hoskins N, Baker-Knight J, et al. The economic burden of insulin-related hypoglycemia in Spain. Diabetes Ther. 2017;8(4):899–913.
  • Pyl J, Dendooven E, Van Eekelen I, et al. Prevalence and prevention of contact dermatitis caused by FreeStyle Libre: a monocentric experience. Diabetes Care. 2020;43(4):918–920.
  • Evans M, Welsh Z, Seibold A. Reductions in HbA1c with flash glucose monitoring are sustained for up to 24 Months: a meta-analysis of 75 real-world observational studies. Diabetes Ther. 2022;13(6):1175–1185.
  • Lage MJ, Boye KS. The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database. Curr Med Res Opin. Internet]. [cited 2022 Jul 5];36. Available from:: https://pubmed.ncbi.nlm.nih.gov/32643451/
  • Boye KS, Lage MJ, Thieu VT. The association between Hba1c and 1-year diabetes-related medical costs: a retrospective claims database analysis. Diabetes Ther. 2022;13(2):367–377.
  • Jiménez-Sahagún R, Gómez Hoyos E, Díaz Soto G, et al. Impact of flash glucose monitoring on quality of life and glycaemic control parameters in adults with type 1 diabetes mellitus⋆. Endocrinol Diabetes Nutr (Engl Ed). 2022;69. 345–353.
  • Lameijer A, Fokkert MJ, Edens MA, et al. Two-year use of flash glucose monitoring is associated with sustained improvement of glycemic control and quality of life (FLARE-NL-6). BMJ Open Diabetes Res Care. Internet]. 2021;9(1):e002124. Available from: http://dx.doi.org/10.1136/bmjdrc-2021-002124
  • Charleer S, De Block C, Van Huffel L, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently Scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care. 2020;43(2):389–397.
  • Tian J, Ohkuma T, Cooper M, et al. Effects of intensive glycemic control on clinical outcomes among patients with type 2 diabetes with different levels of cardiovascular risk and hemoglobin A in the ADVANCE Trial. Diabetes Care. 2020;43(6):1293–1299.
  • Caturano A, Galiero R, Pafundi PC, et al. Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence. Diabetes Res Clin Pract. 2021;178:108959.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.